![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C15H19Cl2NO |
Molar mass | 300.22 g·mol−1 |
3D model (JSmol) | |
| |
(verify) |
NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under developmentbyGlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.[2] The results did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatmentofADHD,[3] phase II having been completed in 2007.[4]Aphase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]
| |
---|---|
2-Carboxymethyl Esters |
|
(3,4-Disubstituted Phenyl)-tropanes |
|
Arylcarboxy |
|
Carboxyalkyl |
|
Acyl |
|
β,α Stereochemistry |
|
α,β Stereochemistry |
|
Heterocycles: 3-Substituted-isoxazol-5-yl |
|
Heterocycles: 3-Substituted-1,2,4-oxadiazole |
|
N-alkyl |
|
N-replaced (S,O,C) |
|
Irreversible |
|
Nortropanes (N-demethylated) |
|
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |